Aelin Therapeutics

Aelin Therapeutics, a privately held Belgian biotherapeutics company, has secured a 27 M€ investment to pioneer a novel modality in drug development in order to create a completely new class of antibiotics and first-in-class therapeutics against high-value undruggable human targets. The technology, branded Pept-ins™, harnesses the power of protein aggregation to specifically induce functional knockdown of a target protein. The company will use the proceeds of the 27 M€ Series A financing, to bring a first Pept-in product to the clinic. 
 
Aelin Therapeutics is founded by VIB and its partner universities KU Leuven, VUB and UGent, based on the groundbreaking work of renowned structural biologists Prof Joost Schymkowitz and Prof Frederic Rousseau.

Website